Non-O blood group and outcomes of in vitro fertilization
- 97 Downloads
Retrospective and cross-sectional studies suggested that non-O blood group may be associated with failures of in vitro fertilization (IVF), but data remain controversial. The aim of this observational cohort study was to prospectively evaluate the effect of non-O blood type on clinical outcomes of IVF.
Women < 40 years who underwent IVF and had ABO blood type recorded as part of the routine workup were eligible. The primary study outcome was live birth. Secondary outcomes included spontaneous abortion, positive pregnancy test, and clinical pregnancy.
A total of 497 women with a mean age of 34.6 (standard deviation 3.2) years were included. The mean number of embryos transferred was 2.3 (standard deviation 0.6). The most common ABO blood types were O (n = 213, 42.9%) and A (n = 203, 40.8%), while 63 (12.7%) and 18 (3.6%) women had the B and AB blood types, respectively. Differences in live birth (21.8 vs. 24.3%, odds ratio [OR] 1.17; 95% confidence intervals [CI], 0.76 to 1.78), positive pregnancy test (37.9 vs. 36.6%, OR 0.96; 95% CI, 0.66 to 1.38), clinical pregnancy (35.1 vs. 33.8%, OR 0.95; 95% CI, 0.66 to 1.39), and spontaneous abortion (12.3 vs. 9.2%, OR 0.72; 95% CI, 0.41 to 1.29) between women with O and non-O blood type were not statistically significant.
In a prospective cohort study, we confirmed the lack of a significant association between non-O blood type and clinical outcomes of IVF. Further studies are needed to clarify whether non-O blood group has any prognostic relevance in women undergoing IVF.
KeywordsABO blood type Thrombophilia Assisted reproductive techniques
Conception and design (MDN, EP); acquisition of data (MDN, AP, GMT, MDG); analysis and interpretation of data (MDN, AWSR, AP, GMT, MDG, EP); drafting the article or revising it critically for important intellectual content (MDN, AWSR, AP, GMT, MDG, EP); final approval of the version to be published (MDN, AWSR, AP, GMT, MDG, EP).
Compliance with ethical standards
Conflict of interest
MDN has received personal fees from Daiichi-Sankyo and Bayer outside the submitted work. All other authors declare that they have no conflict of interest.
All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 13.O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22:335–41.CrossRefPubMedGoogle Scholar
- 24.Pereira N, Patel HH, Stone LD, Christos PJ, Elias RT, Spandorfer SD, et al. Association between ABO blood type and live-birth outcomes in single embryo transfer cycles. Fertil Steril. 2017;S0015-0282(17):31741–7.Google Scholar